Metoprolol

is prescribed to treat:

• High blood pressure (hypertension) • Chest pain (angina) • Heart failure • Abnormal heart rhythms (atrial fibrillation, SVT) • Prevention of migraine headaches • Post-heart attack (improves survival) • Hyperthyroidism symptoms

It helps reduce strain on the heart and prevents cardiovascular events.

Metoprolol (Lopressor, Toprol-XL) is a cardioselective beta blocker used after myocardial infarction, in congestive heart failure with reduced ejection fraction, for rate control in atrial fibrillation, for angina, and for high blood pressure. Its two formulations are not interchangeable, and confusing them is one of the more consequential errors in outpatient cardiology.

Mechanism of Action

Metoprolol blocks beta-1 adrenergic receptors, which are concentrated in cardiac tissue. Blocking them reduces heart rate, contractility, and atrioventricular nodal conduction, which lowers myocardial oxygen demand — the direct reason it relieves angina — and slows the ventricular response in atrial fibrillation. It also suppresses renin release from the kidney, contributing to blood pressure reduction.

Cardioselectivity is relative, not absolute. At low doses metoprolol largely spares beta-2 receptors in bronchial and vascular smooth muscle, which is why it is usable in many patients with asthma or COPD where a non-selective agent such as propranolol would not be. At higher doses that selectivity erodes, so the reassurance is dose-dependent rather than a class guarantee.

In heart failure the mechanism is different and initially counterintuitive: chronic sympathetic overdrive is itself damaging to the failing myocardium, and blunting it produces reverse remodelling and a mortality benefit over months. That benefit belongs to specific agents — metoprolol succinate, carvedilol, and bisoprolol — and is not a class effect. Metoprolol tartrate has not demonstrated it, which is precisely why the formulation distinction matters.

Metoprolol succinate is the extended-release form dosed once daily and is the one proven in heart failure. Metoprolol tartrate is immediate-release, dosed twice daily, and appropriate for rate control or blood pressure but not the evidence-based choice in reduced ejection fraction.

Clinical Use

Metoprolol is standard after myocardial infarction, where beta blockade reduces reinfarction and mortality. In heart failure with reduced ejection fraction, metoprolol succinate is a cornerstone alongside an ACE inhibitor, ARB, or ARNI, an SGLT2 inhibitor, and a mineralocorticoid antagonist such as spironolactone. Started at a low dose and titrated slowly, since abrupt introduction at a high dose can transiently worsen heart failure.

For hypertension, beta blockers are no longer first-line unless there is a compelling additional indication — prior infarction, heart failure, or rate control — because they reduce stroke less effectively than calcium channel blockers, thiazides, and renin-angiotensin agents at equivalent blood pressure reduction. A patient on metoprolol solely for blood pressure, with no cardiac indication, is worth reassessing.

Metoprolol is also used for rate control in atrial fibrillation and atrial flutter, for migraine prophylaxis, for symptomatic control in hyperthyroidism, and for essential tremor. Patients often notice reduced exercise tolerance and blunted maximal heart rate, which is expected physiology rather than a complication, though it matters to athletic patients. The heart palpitations article covers when a rhythm complaint needs evaluation, and our cardiovascular team manages the titration in heart failure.

Monitoring and Follow-Up

Heart rate and blood pressure guide dosing. In heart failure, titration is deliberate: increase every two weeks or slower, watching for worsening fluid retention, fatigue, or hypotension, and accept that transient symptoms during titration are common and usually resolve. Resting heart rate is the practical marker of adequate beta blockade.

Metoprolol is metabolised by CYP2D6, and roughly 7 to 10 percent of people of European ancestry are poor metabolisers who reach substantially higher drug levels at standard doses. Strong CYP2D6 inhibitors, including fluoxetine, paroxetine, and bupropion, produce the same effect pharmacologically — a common and under-recognised cause of unexplained bradycardia or fatigue in a patient started on an antidepressant.

Metoprolol masks the adrenergic warning signs of hypoglycemia — tremor, palpitations, anxiety — while leaving sweating intact. In insulin-treated diabetes this warrants explicit counselling rather than avoidance of the drug. It does not meaningfully worsen glycemic control at usual doses. The MedlinePlus metoprolol entry covers the prescribing detail, and the American Heart Association explains where beta blockers sit in heart failure care.

Special Populations

Metoprolol must never be stopped abruptly. Chronic beta blockade upregulates receptors, and sudden withdrawal produces rebound tachycardia, hypertension, and — in patients with coronary disease — angina or infarction. Taper over one to two weeks.

In asthma and COPD, low-dose cardioselective metoprolol is generally tolerated and the cardiac benefit usually outweighs the respiratory risk, but bronchospasm should be monitored for. It is contraindicated in significant bradycardia, second- or third-degree heart block without a pacemaker, and decompensated heart failure — the drug is started once a patient is stable, not during an acute exacerbation. In pregnancy, beta blockers are used when needed; labetalol is generally preferred. Hepatic impairment slows clearance and warrants lower doses, while kidney impairment does not.

The succinate-versus-tartrate distinction deserves one more word because it causes real harm. Patients discharged on metoprolol succinate for heart failure are sometimes switched to tartrate at a pharmacy or on a subsequent admission, on the reasonable-looking assumption that the difference is only in dosing frequency. It is not: the mortality benefit in reduced ejection fraction was demonstrated with succinate, and substituting tartrate quietly removes an evidence-based therapy while appearing to continue it. Check which formulation is actually on the bottle whenever heart failure is the indication.

When to Contact Your Doctor

Report a resting heart rate persistently below 50, dizziness, fainting, or near-fainting, which suggest excessive bradycardia. Worsening shortness of breath, rapid weight gain, or increasing ankle swelling during titration may mean heart failure is decompensating and needs prompt review. New wheezing warrants evaluation in anyone with airway disease. Marked fatigue, vivid dreams, or low mood are recognised effects and are worth raising rather than enduring. Never stop metoprolol on your own, and if doses have been missed for several days, ask before resuming at the previous dose.

To review your heart rate, blood pressure, or whether your beta blocker still has an indication, contact us or schedule a visit.